Clinician hesitation prior to clozapine initiation: Is it justifiable?

British Journal of Psychiatry

Volumn 201, Issue 6, 2012, Pages 425-427

  Patel, Maxine X ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE;

DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MONITORING; HEALTH PERSONNEL ATTITUDE; HUMAN; HYPERSALIVATION; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 84870311606     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.112.114777     Document Type: Review

References (23)

1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96.
2. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481-5.
3. National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) (Clinical Guideline CG82). NICE, 2009.
4. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003; 64: 30-4. (Pubitemid 36182226)
5. Nielson J, Dahm M, Lublin H, Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010; 24: 965-71.
6. Farooq S, Taylor M. Clozapine: dangerous orphan or neglected friend? Br J Psychiatry 2011; 198: 247-9.
7. Taylor DM, Douglas-Hall P, Olofinjana B, Whiskey E, Thomas A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry 2009; 194: 165-7.
8. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-7.
9. Whiskey E, Olofinjana O, Taylor D. The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study. J Psychopharmacol 2011; 25: 842-5.
10. Pai NB, Vella SC. Reason for clozapine cessation. Acta Psychiatr Scand 2011; 124: 39-44.
11. Taylor D, Paton C, Kapur S. Maudsley Prescribing Guidelines, 11th Edition. Wiley Blackwell, 2012.
12. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet 2009; 373: 31-41.
13. Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry 2011; 199: 281-8.
14. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription for clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715-23. (Pubitemid 44412859)
15. McEvoy JP, Liebermann JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-10. (Pubitemid 44464569)
16. Couchman L, Morgan PE, Spencer EP, Flanagan RJ. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service. Ther Drug Monit 2010; 32: 438-47.
17. Couchman L, Bowskill SV, Handley S, Patel MX, Flanagan RJ. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010. Early Interv Psychiatry 2012; 2 Jul, doi: 10.1111/j.1751-7893.2012. 00374.x (ePub ahead of print).
18. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hopitalization for schizophrenia. Am J Psychiatry 2011; 168: 603-9.
19. Downs J, Zinkler M. Clozapine: national review of postcode prescribing. Psychiatr Bull 2007; 31: 384-7. (Pubitemid 47565022)
20. Patel MX, David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treat 2005; 11: 203-11.
21. Best-Shaw L, Nagar J, David AS, Rose D, Patel MX. Psychiatrists' perspectives regarding antipsychotics: Dose choice and plasma level therapeutic drug monitoring. J Psychopharmacol 2012; 26 (suppl 8): A39.
22. Royal College of Psychiatrists. National Audit of Schizophrenia (NAS). Royal College of Psychiatrists, 2011. (http://www.rcpsych.ac.uk/quality/ nationalclinicalaudits/schizophrenia/nationalschizophreniaaudit.aspx).
23. Harrison PJ, Baldwin DS, Barnes TRE, Burns T, Ebmeier KP, Ferrier IN, et al. No psychiatry without psychopharmacology. Br J Psychiatry 2011; 199: 263-5.